Verneuil Vanina De Sells 13,700 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 13,700 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $9.82, for a total transaction of $134,534.00. Following the completion of the sale, the executive vice president owned 112,982 shares of the company’s stock, valued at $1,109,483.24. This trade represents a 10.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Verneuil Vanina De also recently made the following trade(s):

• On Tuesday, February 24th, Verneuil Vanina De sold 3,117 shares of Vir Biotechnology stock. The stock was sold at an average price of $9.53, for a total transaction of $29,705.01.
• On Monday, February 23rd, Verneuil Vanina De sold 4,445 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.45, for a total value of $33,115.25.

Vir Biotechnology Stock Performance

VIR opened at $9.09 on Friday. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -2.88 and a beta of 1.69. Vir Biotechnology, Inc. has a one year low of $4.16 and a one year high of $10.94. The business’s fifty day moving average is $7.01 and its two-hundred day moving average is $6.07.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. The business had revenue of $64.07 million during the quarter, compared to analysts’ expectations of $19.91 million. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The business’s revenue for the quarter was up 417.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.76) earnings per share. On average, analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Key Stories Impacting Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas agreed to a collaboration on Vir’s prostate‑cancer asset (VIR‑5500) that includes up‑front and potential milestone payments totaling up to ~$1.7B, materially de‑risking that program and improving commercialization prospects. Read More.
• Positive Sentiment: Q4 results surprised to the upside: EPS and roughly $64M revenue beat consensus, signaling stronger commercial traction and likely underpinning recent analyst optimism. Read More.
• Positive Sentiment: Analysts have raised targets and ratings following the results and deal flow (Needham moved its target to $18), supporting upside from fundamentals despite volatility. Read More.
• Neutral Sentiment: Management will present at TD Cowen and Leerink in early March — useful for additional color and Q&A but not an immediate earnings/cash catalyst. Read More.
• Neutral Sentiment: Increased media/peer comparisons (head‑to‑head coverage) have raised visibility and trading volume; this can amplify moves but doesn’t change Vir’s underlying cashflow or pipeline. Read More.
• Negative Sentiment: Vir priced an underwritten offering of 17,647,058 shares at $8.50 (~$150M gross), which strengthens the balance sheet but is dilutive and increased near‑term share supply — a clear short‑term negative for the stock. Read More.
• Negative Sentiment: Market coverage singled out the discounted offering as the proximate cause of the post‑rally pullback, triggering selling and higher volatility. Read More.
• Negative Sentiment: Multiple insider sales were disclosed last week (including CEO and other senior officers/directors), increasing visible supply and feeding negative sentiment alongside the offering. Individual filings and summaries are available in SEC/insider reports. Read More.

Institutional Trading of Vir Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC lifted its holdings in Vir Biotechnology by 2,088.4% during the 1st quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock worth $1,739,000 after buying an additional 256,037 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Vir Biotechnology during the 1st quarter valued at approximately $359,000. Goldman Sachs Group Inc. lifted its stake in Vir Biotechnology by 43.6% during the first quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock worth $4,813,000 after purchasing an additional 225,544 shares during the last quarter. Woodline Partners LP boosted its holdings in Vir Biotechnology by 245.6% in the first quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock worth $3,024,000 after purchasing an additional 331,701 shares during the period. Finally, Focus Partners Wealth increased its stake in Vir Biotechnology by 15.3% during the first quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock valued at $125,000 after purchasing an additional 2,566 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on VIR shares. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a report on Monday, December 22nd. Barclays raised their price objective on Vir Biotechnology from $26.00 to $30.00 and gave the stock an “overweight” rating in a report on Tuesday. Leerink Partners restated an “outperform” rating and set a $20.00 target price on shares of Vir Biotechnology in a report on Thursday. Needham & Company LLC upped their price target on Vir Biotechnology from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Evercore restated an “outperform” rating and set a $18.00 target price on shares of Vir Biotechnology in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.89.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.